Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1642)	9/15/2000 1:40:36 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

Chase came out in support of pcyc today, in an abreviated report I had a chance to see. First speculation/explanantion I've heard about the drug/procedure differences in the non-confirming experiments (its the medium, dumkopf!). Unfortunately, the essence of the Einhorn's report (slow enrollment, etc.) was not addressed. And Lutrin was not mentioned though Antrin for PAD sure was. I can't figure that out. Usual argument: late stage, large market, subtract cash = value worth buying. I dunno, still gives me the heebee jeebees. Wilder